# NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

> **NCT05605496** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 57 (actual)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** NP137
- **DRUG:** anti-PD-1/PD-L1

## Key facts

- **NCT ID:** NCT05605496
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-06
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605496, "NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05605496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*